GLIS1: A Zinc Finger Protein with Potential as a Drug Target or Biomarker

Target Name: GLIS1

NCBI ID: G148979

GLIS1

GLIS1: A Zinc Finger Protein with Potential as a Drug Target or Biomarker

GLIS1, a zinc finger protein, has been identified as a potential drug target or biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to investigate, and its potential as a drug or biomarker has drawn significant interest in the scientific community.

GLIS1 is a protein that contains a zinc finger domain, which is a common structural feature in proteins that plays a crucial role in protein-protein interactions and regulation of gene expression. The zinc finger domain is composed of four amino acids: K, Q, R, and S. It is this domain that gives GLIS1 its unique structure and function.

GLIS1 functions as a negative regulator of the androgen receptor (AR), which is a protein that plays a critical role in the development and progression of cancer. The AR is a nuclear protein that is expressed in various tissues and is involved in the regulation of androgen signaling. GLIS1 has been shown to interact with the AR and prevent it from activating, which has led to the assumption that GLIS1 may be a potential drug target or biomarker for cancer.

In addition to its function as a negative regulator of the AR, GLIS1 has also been shown to play a role in the regulation of cell survival and metabolism. It has been shown to interact with various cellular signaling pathways, including the TGF-β pathway, which is involved in cell growth, differentiation, and survival. GLIS1 has also been shown to be involved in the regulation of cell metabolism, as it has been shown to interact with the protein p53, which is a critical regulator of DNA damage repair.

GLIS1 has also been shown to be involved in the regulation of neural development and function. It has been shown to interact with the protein brain-derived neurotrophic factor (BDNF), which is a protein that promotes brain health and is involved in the development and maintenance of neural circuits. GLIS1 has also been shown to be involved in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time.

In conclusion, GLIS1 is a unique protein that has been shown to play a critical role in the regulation of various cellular processes, including cell survival, metabolism, and neural development and function. Its unique structure and function have made it an attractive target for research into its potential as a drug or biomarker. Further research is needed to fully understand the role of GLIS1 in disease and to develop effective treatments.

Protein Name: GLIS Family Zinc Finger 1

Functions: Acts as both a repressor and activator of transcription (PubMed:21654807). Binds to the consensus sequence 5'-GACCACCCAC-3' (By similarity). By controlling the expression of genes involved in cell differentiation inhibits the lineage commitment of multipotent cells (PubMed:21654807). Prevents, for instance, the differentiation of multipotent mesenchymal cells into adipocyte and osteoblast (By similarity)

The "GLIS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GLIS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets